Airship AI Holdings, Inc. Class A Common Stock
Airship AI Holdings, Inc. provides artificial intelligence (AI)-driven data management surveillance platforms in the United States. The company offers Outpost AI, which structures and analyzes data at the source using Airship AI trained models; Acropolis, an enterprise management software; and Airship Command, a suite of visualization tools that allows customers to interact with their data and devices. Its Acropolis products include Acropolis Commercial for various small and medium businesses, including schools, hospitals, casinos, logistics, and retail establishments; and Acropolis Law for the law enforcement, defense, and intelligence sectors. The company also provides professional services, such as custom model training, custom integrations, and workflow enhancement services, as well as technical support and software maintenance services. It serves the government, enterprises, law enforcement, military, and commercial enterprise organizations. Airship AI Holdings, Inc. was founded in 2006 and is headquartered in Redmond, Washington.
Open AISP dashboard ↗Bullfrog AI Holdings, Inc. Common Stock
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Open BFRG dashboard ↗